V16 Stock Overview
Manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for V16 from our risk checks.
Virbac SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €379.50 |
52 Week High | €392.00 |
52 Week Low | €248.50 |
Beta | 0.95 |
11 Month Change | 5.42% |
3 Month Change | 8.27% |
1 Year Change | 43.21% |
33 Year Change | 5.42% |
5 Year Change | 64.64% |
Change since IPO | 249.45% |
Recent News & Updates
Recent updates
Shareholder Returns
V16 | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 4.5% | -3.9% | 0.02% |
1Y | 43.2% | -15.4% | 11.7% |
Return vs Industry: V16 exceeded the German Pharmaceuticals industry which returned -15.4% over the past year.
Return vs Market: V16 exceeded the German Market which returned 11.7% over the past year.
Price Volatility
V16 volatility | |
---|---|
V16 Average Weekly Movement | 4.3% |
Pharmaceuticals Industry Average Movement | 5.3% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.6% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: V16 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: V16's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1968 | 5,459 | Habib Ramdani | corporate.virbac.com |
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners.
Virbac SA Fundamentals Summary
V16 fundamental statistics | |
---|---|
Market cap | €3.22b |
Earnings (TTM) | €141.19m |
Revenue (TTM) | €1.34b |
22.8x
P/E Ratio2.4x
P/S RatioIs V16 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
V16 income statement (TTM) | |
---|---|
Revenue | €1.34b |
Cost of Revenue | €446.54m |
Gross Profit | €892.83m |
Other Expenses | €751.63m |
Earnings | €141.19m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 16.86 |
Gross Margin | 66.66% |
Net Profit Margin | 10.54% |
Debt/Equity Ratio | 37.2% |
How did V16 perform over the long term?
See historical performance and comparison